Bio-Rad Laboratories, Inc. $BIO Shares Purchased by Plato Investment Management Ltd

Plato Investment Management Ltd grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 211.3% in the 2nd quarter, Holdings Channel reports. The fund owned 1,317 shares of the medical research company’s stock after acquiring an additional 894 shares during the period. Plato Investment Management Ltd’s holdings in Bio-Rad Laboratories were worth $317,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Oppenheimer Asset Management Inc. lifted its stake in shares of Bio-Rad Laboratories by 1.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 2,871 shares of the medical research company’s stock worth $693,000 after acquiring an additional 54 shares in the last quarter. UMB Bank n.a. increased its holdings in Bio-Rad Laboratories by 89.8% during the 2nd quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock worth $40,000 after purchasing an additional 79 shares during the last quarter. Blue Trust Inc. raised its position in shares of Bio-Rad Laboratories by 5.5% in the 2nd quarter. Blue Trust Inc. now owns 1,517 shares of the medical research company’s stock valued at $366,000 after purchasing an additional 79 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its stake in shares of Bio-Rad Laboratories by 10.4% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 994 shares of the medical research company’s stock valued at $242,000 after buying an additional 94 shares during the last quarter. Finally, Louisiana State Employees Retirement System grew its position in shares of Bio-Rad Laboratories by 1.9% during the first quarter. Louisiana State Employees Retirement System now owns 5,400 shares of the medical research company’s stock worth $1,315,000 after buying an additional 100 shares in the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BIO has been the topic of several recent analyst reports. Citigroup upped their price target on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Wells Fargo & Company boosted their target price on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Wall Street Zen raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Finally, Royal Bank Of Canada lifted their target price on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $358.50.

Bio-Rad Laboratories Price Performance

NYSE BIO opened at $311.13 on Tuesday. The company has a 50-day moving average price of $298.98 and a two-hundred day moving average price of $265.87. Bio-Rad Laboratories, Inc. has a 52 week low of $211.43 and a 52 week high of $387.99. The stock has a market cap of $8.42 billion, a price-to-earnings ratio of -12.80 and a beta of 0.97. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Wednesday, October 29th. The medical research company reported $2.26 earnings per share for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.18%. The business had revenue of $653.00 million for the quarter, compared to the consensus estimate of $651.30 million. During the same period last year, the firm posted $2.01 EPS. The business’s quarterly revenue was up .5% on a year-over-year basis. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.